TR200000132T2 - Dolastatin 15 türevleri - Google Patents

Dolastatin 15 türevleri

Info

Publication number
TR200000132T2
TR200000132T2 TR2000/00132T TR200000132T TR200000132T2 TR 200000132 T2 TR200000132 T2 TR 200000132T2 TR 2000/00132 T TR2000/00132 T TR 2000/00132T TR 200000132 T TR200000132 T TR 200000132T TR 200000132 T2 TR200000132 T2 TR 200000132T2
Authority
TR
Turkey
Prior art keywords
group
mammal
amino
formula
dolastatin
Prior art date
Application number
TR2000/00132T
Other languages
English (en)
Turkish (tr)
Inventor
Janssen Bernd
Barlozzari Teresa
Haupt Andreas
Zierke Thomas
Kling Andreas
Original Assignee
Basf Aktiengesellschaft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basf Aktiengesellschaft filed Critical Basf Aktiengesellschaft
Publication of TR200000132T2 publication Critical patent/TR200000132T2/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/06Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12PFERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P19/00Preparation of compounds containing saccharide radicals
    • C12P19/26Preparation of nitrogen-containing carbohydrates
    • C12P19/28N-glycosides
    • C12P19/30Nucleotides
    • C12P19/34Polynucleotides, e.g. nucleic acids, oligoribonucleotides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
TR2000/00132T 1997-07-18 1998-07-07 Dolastatin 15 türevleri TR200000132T2 (tr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/896,394 US6143721A (en) 1997-07-18 1997-07-18 Dolastatin 15 derivatives

Publications (1)

Publication Number Publication Date
TR200000132T2 true TR200000132T2 (tr) 2000-05-22

Family

ID=25406130

Family Applications (2)

Application Number Title Priority Date Filing Date
TR2000/00132T TR200000132T2 (tr) 1997-07-18 1998-07-07 Dolastatin 15 türevleri
TR2001/03545T TR200103545T2 (tr) 1997-07-18 1998-07-07 Dolastatin 15-türevleri.

Family Applications After (1)

Application Number Title Priority Date Filing Date
TR2001/03545T TR200103545T2 (tr) 1997-07-18 1998-07-07 Dolastatin 15-türevleri.

Country Status (32)

Country Link
US (6) US6143721A (enExample)
EP (1) EP0991658B1 (enExample)
JP (4) JP4508413B2 (enExample)
KR (1) KR100579748B1 (enExample)
CN (1) CN1268636C (enExample)
AR (1) AR018501A1 (enExample)
AT (1) ATE314387T1 (enExample)
AU (1) AU750120B2 (enExample)
BG (1) BG65212B1 (enExample)
BR (1) BR9810911A (enExample)
CA (1) CA2296036C (enExample)
CO (1) CO4990967A1 (enExample)
CY (1) CY1107047T1 (enExample)
CZ (1) CZ303045B6 (enExample)
DE (1) DE69832982T2 (enExample)
DK (1) DK0991658T3 (enExample)
ES (1) ES2258819T3 (enExample)
HR (1) HRP980397A2 (enExample)
HU (1) HU228996B1 (enExample)
ID (1) ID24669A (enExample)
IL (1) IL133784A (enExample)
MY (1) MY135057A (enExample)
NO (1) NO326827B1 (enExample)
NZ (1) NZ502296A (enExample)
PL (1) PL197884B1 (enExample)
PT (1) PT991658E (enExample)
RU (1) RU2195462C2 (enExample)
SK (1) SK286581B6 (enExample)
TR (2) TR200000132T2 (enExample)
TW (1) TW533217B (enExample)
WO (1) WO1999003879A1 (enExample)
ZA (1) ZA986358B (enExample)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010009901A1 (en) * 1996-12-11 2001-07-26 Basf Aktiengesellschaft Germany Antineoplastic peptides
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
WO2001058928A1 (en) * 2000-02-08 2001-08-16 Nagasawa Herbert T N-terminal d(-)-penicillamine peptides as aldehyde sequestration agents
US7256257B2 (en) * 2001-04-30 2007-08-14 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
US6884869B2 (en) * 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
NZ555951A (en) * 2002-03-22 2009-01-31 Eisai Co Ltd Hemiasterlin derivatives and uses thereof
US7064211B2 (en) * 2002-03-22 2006-06-20 Eisai Co., Ltd. Hemiasterlin derivatives and uses thereof
EP2353611B1 (en) * 2002-07-31 2015-05-13 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
PT2489364E (pt) 2003-11-06 2015-04-16 Seattle Genetics Inc Compostos de monometilvalina conjugados com anticorpos
WO2006063135A2 (en) * 2004-12-09 2006-06-15 Eisai R & D Management Co., Ltd. Tubulin isotype screnning in cancer therapy using hemiasterlin analogs
CA2607940C (en) 2005-05-18 2009-12-15 Aegera Therapeutics Inc. Bir domain binding compounds
SG10201407457UA (en) 2006-05-16 2014-12-30 Pharmascience Inc Iap bir domain binding compounds
DK2176296T3 (da) 2007-07-16 2012-05-21 Genentech Inc Anti-CD79B-antistoffer og immunkonjugater og anvendelsesfremgangsmåder.
WO2009012256A1 (en) 2007-07-16 2009-01-22 Genentech, Inc. Humanized anti-cd79b antibodies and immunoconjugates and methods of use
DE102007039706A1 (de) 2007-08-22 2009-02-26 Erhard Prof. Dr.-Ing. Kohn Chemischer Sensor auf Diamantschichten
DK2247620T3 (en) 2008-01-31 2016-08-22 Genentech Inc ANTI-CD79b ANTIBODIES AND IMMUNOCONJUGATES AND METHODS OF USE
KR20120118008A (ko) * 2009-12-18 2012-10-25 아이데닉스 파마슈티칼스, 인코포레이티드 5,5-융합 아릴렌 또는 헤테로아릴렌 간염 c 바이러스 억제제
KR20130009760A (ko) 2010-02-10 2013-01-23 이뮤노젠 아이엔씨 Cd20 항체 및 이의 용도
KR20120140658A (ko) 2010-02-12 2012-12-31 파마사이언스 인크. Iap bir 도메인 결합 화합물
JP6133431B2 (ja) 2012-11-24 2017-05-24 ハンジョウ ディーエーシー バイオテック シーオー.,エルティディ.Hangzhou Dac Biotech Co.,Ltd. 親水性連結体及び薬物分子と細胞結合分子との共役反応における親水性連結体の使用
US10464955B2 (en) 2014-02-28 2019-11-05 Hangzhou Dac Biotech Co., Ltd. Charged linkers and their uses for conjugation
AU2015320678B2 (en) 2014-09-23 2021-07-22 Genentech, Inc. Method of using anti-CD79b immunoconjugates
CA2989269C (en) 2015-06-15 2020-09-22 Robert Yongxin Zhao Hydrophilic linkers for conjugation of a cytotoxic agent or chromophore molecule to a cell-binding molecule
EP3319936B1 (en) 2015-07-12 2025-12-17 Hangzhou Dac Biotech Co., Ltd. Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
KR20220147721A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
US20250281630A1 (en) 2021-09-03 2025-09-11 Toray Industries, Inc. Pharmaceutical composition for cancer treatment and/or prevention
AU2021362997A1 (en) 2021-11-03 2024-05-16 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816444A (en) * 1987-07-10 1989-03-28 Arizona Board Of Regents, Arizona State University Cell growth inhibitory substance
US4879278A (en) * 1989-05-16 1989-11-07 Arizona Board Of Regents Isolation and structural elucidation of the cytostatic linear depsipeptide dolastatin 15
EP0934950B1 (en) * 1991-08-09 2002-04-10 Teikoku Hormone Mfg. Co., Ltd. Tetrapeptide derivative
US5448045A (en) * 1992-02-26 1995-09-05 Clark; Paul C. System for protecting computers via intelligent tokens or smart cards
US5533097A (en) * 1992-02-26 1996-07-02 Motorola, Inc. Portable communication system comprising a local and wide area communication units which can store a communication when the wide area communication system is not available
US5831002A (en) * 1992-05-20 1998-11-03 Basf Aktiengesellschaft Antitumor peptides
JP3523253B2 (ja) * 1992-05-20 2004-04-26 アボット ゲーエムベーハー ウント カンパニー カーゲー ドラスタチン誘導体
PL178766B1 (pl) * 1992-12-16 2000-06-30 Basf Ag Nowe peptydy
US5554993A (en) * 1994-01-04 1996-09-10 Panasonic Technologies, Inc. Global position determining system and method
US5530097A (en) * 1994-08-01 1996-06-25 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory peptide amides
US5504191A (en) * 1994-08-01 1996-04-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide methyl esters
US5554725A (en) * 1994-09-14 1996-09-10 Arizona Board Of Regents Acting On Behalf Of Arizona State University Synthesis of dolastatin 15
US5663149A (en) * 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
US5618232A (en) * 1995-03-23 1997-04-08 Martin; John R. Dual mode gaming device methods and systems
US5970143A (en) * 1995-11-22 1999-10-19 Walker Asset Management Lp Remote-auditing of computer generated outcomes, authenticated billing and access control, and software metering system using cryptographic and other protocols
US5807984A (en) * 1995-11-09 1998-09-15 Basf Aktienegesellschaft Oligopeptides, the preparation and use thereof
TW474946B (en) * 1995-12-15 2002-02-01 Basf Ag Novel compounds, the preparation and use thereof
CA2287379C (en) * 1997-01-10 2005-10-04 Silicon Gaming-Nevada Method and apparatus for providing authenticated, secure on-line communication between remote locations
US6143721A (en) * 1997-07-18 2000-11-07 Basf Aktiengesellschaft Dolastatin 15 derivatives
US6554705B1 (en) * 1997-08-22 2003-04-29 Blake Cumbers Passive biometric customer identification and tracking system
US6629591B1 (en) * 2001-01-12 2003-10-07 Igt Smart token
US6438382B1 (en) * 2001-02-14 2002-08-20 Telefonaktiebolaget Lm Ericsson (Publ.) Expedited location determination in analog service areas

Also Published As

Publication number Publication date
NO20000231D0 (no) 2000-01-17
HRP980397A2 (en) 1999-04-30
KR20010021998A (ko) 2001-03-15
SK187999A3 (en) 2000-09-12
PL338144A1 (en) 2000-09-25
HU228996B1 (hu) 2013-07-29
IL133784A (en) 2005-09-25
IL133784A0 (en) 2001-04-30
ZA986358B (en) 2000-01-17
PT991658E (pt) 2006-05-31
TW533217B (en) 2003-05-21
NO20000231L (no) 2000-01-17
DK0991658T3 (da) 2006-05-15
HUP0004234A2 (hu) 2001-05-28
US7662786B2 (en) 2010-02-16
JP2001515010A (ja) 2001-09-18
JP2012211164A (ja) 2012-11-01
EP0991658B1 (en) 2005-12-28
US20100099843A1 (en) 2010-04-22
ID24669A (id) 2000-07-27
DE69832982T2 (de) 2006-08-24
CY1107047T1 (el) 2012-09-26
HK1029125A1 (en) 2001-03-23
WO1999003879A1 (en) 1999-01-28
JP5122429B2 (ja) 2013-01-16
JP5047935B2 (ja) 2012-10-10
CN1264388A (zh) 2000-08-23
US6143721A (en) 2000-11-07
BG104089A (en) 2000-12-29
AR018501A1 (es) 2001-11-28
KR100579748B1 (ko) 2006-05-15
US7084110B2 (en) 2006-08-01
MY135057A (en) 2008-01-31
CO4990967A1 (es) 2000-12-26
US6458765B1 (en) 2002-10-01
CN1268636C (zh) 2006-08-09
NZ502296A (en) 2002-02-01
RU2195462C2 (ru) 2002-12-27
PL197884B1 (pl) 2008-05-30
JP4508413B2 (ja) 2010-07-21
ES2258819T3 (es) 2006-09-01
ATE314387T1 (de) 2006-01-15
CZ2000176A3 (en) 2001-06-13
AU8475898A (en) 1999-02-10
BG65212B1 (bg) 2007-07-31
CA2296036C (en) 2007-05-01
US20030153505A1 (en) 2003-08-14
BR9810911A (pt) 2000-08-01
US8163698B2 (en) 2012-04-24
JP2009137967A (ja) 2009-06-25
HUP0004234A3 (en) 2001-08-28
US20130046077A1 (en) 2013-02-21
US20060270606A1 (en) 2006-11-30
CZ303045B6 (cs) 2012-03-07
SK286581B6 (sk) 2009-01-07
EP0991658A1 (en) 2000-04-12
NO326827B1 (no) 2009-02-23
TR200103545T2 (tr) 2002-06-21
CA2296036A1 (en) 1999-01-28
AU750120B2 (en) 2002-07-11
JP2009137968A (ja) 2009-06-25
DE69832982D1 (de) 2006-02-02

Similar Documents

Publication Publication Date Title
TR200000132T2 (tr) Dolastatin 15 türevleri
TR200000481T2 (tr) N-Alkonoilfenilalenin türevleri.
PT1005445E (pt) Derivados de n-alcanoilfenilalanina
IL152659A (en) Liquid pharmaceutical compositions comprising a pegylated human erythropoietin protein and a multiple charged inorganic anion, in a pharmaceutically acceptable buffer
WO2002048183A3 (en) Compositions of peptide crystals
CY1113969T1 (el) Ανευ-αλβουμινης συνταγοποιησεις παραγοντα viii
FI971776A0 (fi) Yhdisteet ja koostumukset aktiivisten aineiden antamiseksi
ES2178000T3 (es) Composiciones y metodos para tratar infecciones usando analogos de indolicidina.
TR200200843T2 (tr) İşemi'nin Tedavisi için olan bileşikler
BR9811099A (pt) Inibidores de urocinase
HUP0000492A1 (hu) N-(Aril/heteroaril-acetil)-aminosav-észterek, azokat tartalmazó gyógyászati készítmények, valamint módszerek béta-amiloid fehérje képződése és felszabadulása gátlására e vegyületek felhasználásával
CY1110801T1 (el) Μεθοδοι και συνθεσεις για την προληψη και θεραπεια της αναιμιας
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
ATE348883T1 (de) Zusammensetzungen und verfahren mit analogen von g-csf
TR200302242T2 (tr) Protein kinaz önleyicileri olarak pirolopirimidinler
CY1115918T1 (el) Συνθεσεις βασιζομενες επι διακλαδισμενης αλυσου αμινοξεων για βελτιωση της μυοκαρδιακης κοιλιακης λειτουργιας σε ασθενεις που υποφερουν απο διαβητη
TR199802534T2 (xx) Leptin (OB Protein) fragmanlar�
TR200201244T2 (tr) Göz kurumasının iyileştirilmesi için Lipoksin A4 ve analogları
NZ326238A (en) Compositons and methods for inhibiting nonenzymatic cross-linking and glycosylation (protein aging) using N-acylaminoalkylhydrazine carboximidamides
ATE286139T1 (de) Replikationskompetente anti-tumor vektoren
NO20031671L (no) Dioksolananaloger for forbedret intercellulaer avlevering
PT1149910E (pt) Composicao farmaceutica contra os tumores e as infeccoes por papilomavirus
CY1107990T1 (el) Τριπεπτιδια και παραγωγα τριπεπτιδιων για τη θepαπεια νευροεκφυλιστικων ασθενειων
IL148874A0 (en) Sulfonyl amino acid derivatives, their preparation and pharmaceutical compositions containing them
NO955067L (no) FVII/TF peptider